<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="96c6a282-3d83-49a3-a050-dab812412de7"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		<br/>
      <br/>TABRECTA<sup>Â®</sup> (capmatinib) tablets, for oral use
		<br/>
		Initial U.S. Approval: 2020
		<br/>
   </title>
   <effectiveTime value="20250327"/>
   <setId root="455892c3-d144-4ba8-9ab4-79cabff9876d"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="002147023" root="1.3.6.1.4.1.519.1"/>
            <name>Novartis Pharmaceuticals Corporation</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="6ff0f09b-71f7-4d9d-8e58-ffcbf24c2028"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230309"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0078-0709" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TABRECTA</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>capmatinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2A374O70X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CAPMATINIB HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TY34L4F9OZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CAPMATINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="56"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0078-0709-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200506"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="56"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0078-0709-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200506"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213591" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200506"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText>Pale orange brown</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>ovaloid, curved</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">DU;NVR</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0078-0716" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TABRECTA</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>capmatinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2A374O70X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CAPMATINIB HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TY34L4F9OZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CAPMATINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="56"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0078-0716-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200506"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="56"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0078-0716-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200506"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213591" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200506"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="20" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>ovaloid, curved</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LO;NVR</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="e2c9857b-9683-4039-81b0-ecabf41b32ec"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1Â Â Â Â Â INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.</paragraph>
               </text>
               <effectiveTime value="20220810"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="5f3b30fd-57c7-4464-9fd7-7ad973b4b2b3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2Â Â Â Â Â DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230324"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Select patients for treatment with TABRECTA based on presence of a mutation that leads to MET exon 14 skipping. (<linkHtml href="#s2p1">2.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Recommended Dosage</content>: 400 mg orally twice daily with or without food. (<linkHtml href="#s2p2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2p1">
                     <id root="b9682802-5402-4026-af31-5445284e56dd"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1Â Â Â Â Â Patient Selection</title>
                     <text>
                        <paragraph>Select patients for treatment with TABRECTA based on the presence of a mutation that leads to MET exon 14 skipping in tumor or plasma specimens <content styleCode="italics">[see Clinical Studies (14)]</content>. If a mutation that leads to MET exon 14 skipping is not detected in a plasma specimen, test tumor tissue if feasible. Information on FDA-approved tests is available at: <linkHtml href="http://www.fda.gov/CompanionDiagnostics">http://www.fda.gov/CompanionDiagnostics</linkHtml>.</paragraph>
                     </text>
                     <effectiveTime value="20230324"/>
                  </section>
               </component>
               <component>
                  <section ID="s2p2">
                     <id root="571e5166-6ffc-4b25-ae68-174ad29c60ce"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2Â Â Â Â Â Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of TABRECTA is 400 mg orally twice daily with or without food.</paragraph>
                        <paragraph>Swallow TABRECTA tablets whole. Do not break, crush or chew the tablets.</paragraph>
                        <paragraph>If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s2p3">
                     <id root="eab36456-aa12-42ae-830a-9f5d645a16b2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3Â Â Â Â Â Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>The recommended dose reductions for the management of adverse reactions are listed in Table 1.</paragraph>
                        <table>
                           <caption>Table 1: Recommended TABRECTA Dose Reductions for Adverse Reactions</caption>
                           <col width="200"/>
                           <col width="200"/>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Dose reduction</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Dose and schedule</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " valign="top">First</td>
                                 <td align="center" styleCode="Toprule " valign="top">300 mg orally  twice daily</td>
                              </tr>
                              <tr>
                                 <td valign="top">Second</td>
                                 <td align="center" valign="top">200 mg orally twice daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Permanently discontinue TABRECTA in patients who are unable to tolerate 200 mg orally twice daily.</paragraph>
                        <paragraph>The recommended dosage modifications of TABRECTA for adverse reactions are provided in Table 2.</paragraph>
                        <table>
                           <caption>Table 2: Recommended TABRECTA Dosage Modifications for Adverse Reactions</caption>
                           <col width="200"/>
                           <col width="200"/>
                           <col width="300"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ILD, interstitial lung disease; ULN, upper limit of normal.<br/>Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule" align="center">
                                    <content styleCode="bold">Adverse reaction</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Botrule" align="center">
                                    <content styleCode="bold">Severity</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Botrule" align="center">
                                    <content styleCode="bold">Dosage modification</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Interstitial Lung Disease (ILD)/Pneumonitis<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Any grade</td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule" valign="top" rowspan="2">Increased ALT and/or AST without increased total bilirubin<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 3</td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Withhold TABRECTA until recovery to baseline ALT/AST.<br/>
                                    <br/>If recovered to baseline within 7 days, then resume TABRECTA at the same dose; otherwise resume TABRECTA at a reduced dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">ALT and/or AST greater than 3 times ULN with total bilirubin greater than 2 times ULN</td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule" valign="top" rowspan="3">Increased total bilirubin without concurrent increased ALT and/or AST<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 2</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Withhold TABRECTA until recovery to baseline bilirubin.<br/>
                                    <br/>If recovered to baseline within 7 days, then resume TABRECTA at the same dose; otherwise resume TABRECTA at a reduced dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 3</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Withhold TABRECTA until recovery to baseline bilirubin.<br/>
                                    <br/>If recovered to baseline within 7 days, then resume TABRECTA at a reduced dose; otherwise permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Increased lipase or amylase<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 3</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Withhold TABRECTA until â¤ Grade 2 or baseline.<br/>
                                    <br/>If recovered to baseline or â¤ Grade 2 within 14 days, resume TABRECTA at a reduced dose; otherwise permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule">Pancreatitis<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Grade 3 or Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Toprule Lrule Rrule">Hypersensitivity<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">All Grades</td>
                                 <td styleCode="Toprule Lrule Rrule" valign="top">If hypersensitivity is suspected based on clinical judgment, withhold TABRECTA until resolution of the event.<br/>Permanently discontinue TABRECTA in patients who develop serious hypersensitivity reactions.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" valign="top" rowspan="3">Other adverse reactions<br/>
                                    <content styleCode="italics">[see Adverse Reactions (6.1)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 2</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Maintain dose level. If intolerable, consider withholding TABRECTA until resolved, then resume TABRECTA at a reduced dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 3</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Withhold TABRECTA until resolved, then resume TABRECTA at a reduced dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="top">Permanently discontinue TABRECTA.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230324"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="e43a18b1-ef08-4eda-a9ae-1e465bc77abb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3Â Â Â Â Â DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets:</paragraph>
                  <list>
                     <item>150 mg: pale orange brown, ovaloid, curved film-coated with beveled edges, unscored, debossed with âDUâ on one side and âNVRâ on the other side</item>
                     <item>200 mg: yellow, ovaloid, curved film-coated with beveled edges, unscored, debossed with âLOâ on one side and âNVRâ on the other side</item>
                  </list>
               </text>
               <effectiveTime value="20200506"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 150 mg and 200 mg</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="cec0fd28-d333-4c6b-ac68-f58611cb434c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4Â Â Â Â Â CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20200506"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="59041bfc-60bf-4784-b8f7-2115322a4dc2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5Â Â Â Â Â WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>: Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue TABRECTA in patients with ILD/pneumonitis. (<linkHtml href="#s2p3">2.3</linkHtml>, <linkHtml href="#s5p1">5.1</linkHtml>)
									</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Monitor liver function tests. Withhold, dose reduce, or permanently discontinue TABRECTA based on severity. (<linkHtml href="#s2p3">2.3</linkHtml>, <linkHtml href="#s5p2">5.2</linkHtml>)
									</item>
                           <item>
                              <content styleCode="underline">Pancreatic Toxicity</content>: Monitor amylase and lipase levels. Withhold, dose reduce, or permanently discontinue TABRECTA based on severity. (<linkHtml href="#s2p3">2.3</linkHtml>, <linkHtml href="#s5p3">5.3</linkHtml>)
									</item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Withhold or permanently discontinue TABRECTA based on severity. (<linkHtml href="#s2p3">2.3</linkHtml>, <linkHtml href="#s5p4">5.4</linkHtml>)
									</item>
                           <item>
                              <content styleCode="underline">Risk of Photosensitivity</content>: May cause photosensitivity reactions. Advise patients to limit direct ultraviolet exposure. (<linkHtml href="#s5p5">5.5</linkHtml>)
									</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#s5p6">5.6</linkHtml>, <linkHtml href="#s8p1">8.1</linkHtml>, <linkHtml href="#s8p3">8.3</linkHtml>)
									</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5p1">
                     <id root="665da48d-9630-406a-8a28-d541f708d7d8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1Â Â Â Â Â Interstitial Lung Disease (ILD)/Pneumonitis</title>
                     <text>
                        <paragraph>ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in GEOMETRY mono-1, with 1.9% of patients experiencing Grade 3 ILD/pneumonitis and one patient experiencing death (0.3%). Nine patients (2.4%) discontinued TABRECTA due to ILD/pneumonitis. The median time-to-onset of Grade 3 or higher ILD/pneumonitis was 1.8 months (range: 0.2 months to 1.7 years).</paragraph>
                        <paragraph>Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold TABRECTA in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified <content styleCode="italics">[see Dosage and Administration (2.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220810"/>
                  </section>
               </component>
               <component>
                  <section ID="s5p2">
                     <id root="458648dd-c66d-4881-af5a-13e9e5e10c91"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2Â Â Â Â Â Hepatotoxicity</title>
                     <text>
                        <paragraph>Hepatotoxicity occurred in patients treated with TABRECTA <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. Increased alanine aminotransferase (ALT)/aspartate aminotransferase (AST) occurred in 15% of patients treated with TABRECTA in GEOMETRY mono-1. Grade 3 or 4 increased ALT/AST occurred in 7% of patients. Three patients (0.8%) discontinued TABRECTA due to increased ALT/AST. The median time-to-onset of Grade 3 or higher increased ALT/AST was 1.8 months (range: 0.5 to 46.4 months).</paragraph>
                        <paragraph>Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TABRECTA, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue TABRECTA <content styleCode="italics">[see Dosage and Administration (2.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220810"/>
                  </section>
               </component>
               <component>
                  <section ID="s5p3">
                     <id root="eace70e1-a680-48ac-96e5-65b9d8f5849c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3Â Â Â Â Â Pancreatic Toxicity</title>
                     <text>
                        <paragraph>Elevations in amylase and lipase levels occurred in patients treated with TABRECTA <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. Increased amylase/lipase occurred in 14% of patients treated with TABRECTA in GEOMETRY mono-1. Grade 3 and 4 increased amylase/lipase occurred in 7% and 1.9% of patients, respectively. Three patients (0.8%) discontinued TABRECTA due to increased amylase/lipase. The median time-to-onset of Grade 3 or higher increased amylase/lipase was 2 months (range: 0.03 to 31.1 months). Pancreatitis (Grade 3) occurred in one patient (0.3%); TABRECTA was permanently discontinued for this event.</paragraph>
                        <paragraph>Monitor amylase and lipase at baseline and regularly during treatment with TABRECTA. Based on the severity of the adverse reaction, temporarily withhold, dose reduce, or permanently discontinue TABRECTA <content styleCode="italics">[see Dosage and Administration (2.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240314"/>
                  </section>
               </component>
               <component>
                  <section ID="s5p4">
                     <id root="190d4ce7-7e1b-499c-a475-8cacf49e342c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4Â Â Â Â Â Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Serious hypersensitivity reactions occurred in patients treated with TABRECTA in clinical trials other than GEOMETRY mono-1 <content styleCode="italics">[see Adverse Reactions (6.1)]</content>. Signs and symptoms of hypersensitivity included pyrexia, chills, pruritus, rash, decreased blood pressure, nausea and vomiting. Based on the severity of the adverse reaction, temporarily withhold or permanently discontinue TABRECTA <content styleCode="italics">[see Dosage and Administration (2.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240314"/>
                  </section>
               </component>
               <component>
                  <section ID="s5p5">
                     <id root="3986e279-4255-4cff-9462-c77892d0b756"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5Â Â Â Â Â Risk of Photosensitivity</title>
                     <text>
                        <paragraph>Based on findings from animal studies, there is a potential risk of photosensitivity reactions with TABRECTA <content styleCode="italics">[see Nonclinical Toxicology (13.2)]</content>. In GEOMETRY mono-1, it was recommended that patients use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing during treatment with TABRECTA. Advise patients to limit direct ultraviolet exposure during treatment with TABRECTA.</paragraph>
                     </text>
                     <effectiveTime value="20230324"/>
                  </section>
               </component>
               <component>
                  <section ID="s5p6">
                     <id root="b74104ff-2d31-463d-b4c4-9879dcb31667"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6Â Â Â Â Â Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal studies and  its mechanism of action, TABRECTA can cause fetal harm when administered to a pregnant woman. Oral administration of capmatinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at exposures less than the human exposure based on area under the curve (AUC) at the 400 mg twice daily clinical dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (8.1, 8.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230324"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="0f267e4a-fa11-480b-83bb-b60123eaaac0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6Â Â Â Â Â ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list>
                     <item>ILD/Pneumonitis <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                     </item>
                     <item>Pancreatic Toxicity <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â¥ 20%) are edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite. (<linkHtml href="#s6">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6p1">
                     <id root="b444ec94-ae92-4c0e-a2d0-8f4e19ea927c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1Â Â Â Â Â Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metastatic Non-Small Cell Lung Cancer</content>
                        </paragraph>
                        <paragraph>The safety of TABRECTA was evaluated in GEOMETRY mono-1 <content styleCode="italics">[see Clinical Studies (14)]</content>. Patients received TABRECTA 400 mg orally twice daily until disease progression or unacceptable toxicity (N = 373). Among patients who received TABRECTA, 37% were exposed for at least 6 months and 22% were exposed for at least one year.</paragraph>
                        <paragraph>Serious adverse reactions occurred in 53% of patients who received TABRECTA. Serious adverse reactions in â¥ 2% of patients included dyspnea (7%), pneumonia (7%), pleural effusion (4.3%), musculoskeletal pain (3.8%), general physical health deterioration (2.9%), ILD/pneumonitis (2.7%), edema (2.4%), and vomiting (2.4%). Fatal adverse reactions occurred in 0.5% of patients who received TABRECTA, including pneumonitis (0.3%) and death, not otherwise specified (0.3%).</paragraph>
                        <paragraph>Permanent discontinuation of TABRECTA due to an adverse reaction occurred in 17% of patients. The most frequent adverse reactions (â¥ 1%) leading to permanent discontinuation of TABRECTA were ILD/pneumonitis (2.4%), edema (2.4%), fatigue (1.3%), and pneumonia (1.1%).</paragraph>
                        <paragraph>Dose interruptions due to an adverse reaction occurred in 57% of patients who received TABRECTA. Adverse reactions requiring dosage interruption in &gt; 2% of patients who received TABRECTA included edema, increased blood creatinine, nausea, increased lipase, vomiting, increased ALT, dyspnea, pneumonia, fatigue, increased amylase, increased AST, musculoskeletal pain, abdominal pain, and increased blood bilirubin.</paragraph>
                        <paragraph>Dose reductions due to an adverse reaction occurred in 26% of patients who received TABRECTA. Adverse reactions requiring dosage reductions in &gt; 2% of patients who received TABRECTA included edema, increased ALT and increased blood creatinine.</paragraph>
                        <paragraph>The most common adverse reactions (â¥ 20%) in patients who received TABRECTA were edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.</paragraph>
                        <paragraph>Table 3 summarizes the adverse reactions in GEOMETRY mono-1.</paragraph>
                        <table>
                           <caption>Table 3: Adverse Reactions (â¥ 10%) in Patients Who Received TABRECTA in GEOMETRY mono-1</caption>
                           <col width="450"/>
                           <col width="285"/>
                           <col width="285"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup>Edema includes edema peripheral, generalized edema, face edema, edema, localized edema, edema genital, eyelid edema, peripheral swelling, scrotal edema, and penile edema.<br/>
                                    <sup>b</sup>Musculoskeletal pain includes arthralgia, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, spinal pain.<br/>
                                    <sup>c</sup>Fatigue includes fatigue and asthenia.<br/>
                                    <sup>d</sup>Pyrexia includes pyrexia and body temperature increased.<br/>
                                    <sup>e</sup>Cough includes cough, upper airway cough syndrome, and productive cough.<br/>
                                    <sup>f</sup>Pneumonia includes pneumonia aspiration, pneumonia, pneumonia influenzal, pneumonia bacterial, lower respiratory tract infection, and lung abscess.<br/>
                                    <sup>g</sup>Rash includes rash, dermatitis acneiform, rash maculo-papular, eczema, erythema multiforme, rash macular, dermatitis, rash erythematous, rash pustular, dermatitis bullous, and rash vesicular.<br/>
                                    <sup>h</sup>Dizziness includes dizziness, vertigo, and vertigo positional.
											</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Adverse reactions</content>
                                 </td>
                                 <td colspan="2" align="center">
                                    <content styleCode="bold">TABRECTA<br/>(N = 373)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Grades 1 to 4<br/>(%)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Grades 3 to 4
													<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule" colspan="3" align="left">
                                    <content styleCode="bold">General disorders and administration-site conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Edema<sup>a</sup>
                                 </td>
                                 <td align="center">59</td>
                                 <td align="center">13</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Musculoskeletal pain<sup>b</sup>
                                 </td>
                                 <td align="center">40</td>
                                 <td align="center">4.3</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Fatigue<sup>c</sup>
                                 </td>
                                 <td align="center">34</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Pyrexia<sup>d</sup>
                                 </td>
                                 <td align="center">14</td>
                                 <td align="center">0.8</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Weight decreased</td>
                                 <td align="center">11</td>
                                 <td align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Nausea
											</td>
                                 <td align="center">46</td>
                                 <td align="center">2.4</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Vomiting
											</td>
                                 <td align="center">28</td>
                                 <td align="center">2.4</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Constipation
											</td>
                                 <td align="center">19</td>
                                 <td align="center">0.8</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Diarrhea
											</td>
                                 <td align="center">19</td>
                                 <td align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Dyspnea</td>
                                 <td align="center">25</td>
                                 <td align="center">7
											</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Cough<sup>e</sup>
                                 </td>
                                 <td align="center">21</td>
                                 <td align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Pneumonia<sup>f</sup>
                                 </td>
                                 <td align="center">13</td>
                                 <td align="center">6</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased appetite</td>
                                 <td align="center">21</td>
                                 <td align="center">1.1</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Rash<sup>g</sup>
                                 </td>
                                 <td align="center">13</td>
                                 <td align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Dizziness<sup>h</sup>
                                 </td>
                                 <td align="center">13</td>
                                 <td align="center">0.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions occurring in &lt; 10% of patients treated with TABRECTA included pruritus (including allergic pruritus), ILD/pneumonitis, cellulitis, acute kidney injury (including renal failure), urticaria, and acute pancreatitis.</paragraph>
                        <paragraph>Table 4 summarizes the laboratory abnormalities in GEOMETRY mono-1.</paragraph>
                        <table>
                           <caption>Table 4: Select Laboratory Abnormalities (â¥ 20%) Worsening From Baseline in Patients Who Received TABRECTA in GEOMETRY mono-1</caption>
                           <col width="450"/>
                           <col width="285"/>
                           <col width="285"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup>The denominator used to calculate the rate varied from 359 to 364 based on the number of patients with a baseline value and at least one post-treatment value.
											</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Laboratory abnormalities</content>
                                 </td>
                                 <td colspan="2" align="center">
                                    <content styleCode="bold">TABRECTA<sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Grades 1 to 4<br/>(%)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Grades 3 to 4<br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule" colspan="3" align="left">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased albumin</td>
                                 <td align="center">72</td>
                                 <td align="center">1.9</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased creatinine</td>
                                 <td align="center">65</td>
                                 <td align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased alanine aminotransferase</td>
                                 <td align="center">39</td>
                                 <td align="center">9</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased amylase</td>
                                 <td align="center">34</td>
                                 <td align="center">4.7</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased alkaline phosphatase</td>
                                 <td align="center">32</td>
                                 <td align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased gamma-glutamyltransferase</td>
                                 <td align="center">30</td>
                                 <td align="center">6</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased lipase</td>
                                 <td align="center">29</td>
                                 <td align="center">9</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased aspartate aminotransferase</td>
                                 <td align="center">28</td>
                                 <td align="center">6</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased phosphate</td>
                                 <td align="center">26</td>
                                 <td align="center">4.4</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Increased potassium</td>
                                 <td align="center">25</td>
                                 <td align="center">4.1</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased sodium</td>
                                 <td align="center">24</td>
                                 <td align="center">6</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased glucose</td>
                                 <td align="center">23</td>
                                 <td align="center">0.3</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased lymphocytes
											</td>
                                 <td align="center">45</td>
                                 <td align="center">14</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased leukocytes
											</td>
                                 <td align="center">25</td>
                                 <td align="center">1.7</td>
                              </tr>
                              <tr>
                                 <td>Â Â Â Â Â Decreased hemoglobin
											</td>
                                 <td align="center">24</td>
                                 <td align="center">2.8</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Other Clinical Trials Experience</content>
                        </paragraph>
                        <paragraph>The following adverse reactions have been reported following administration of TABRECTA: hypersensitivity and thrombocytopenia.</paragraph>
                     </text>
                     <effectiveTime value="20240314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="3c14faad-cc27-495d-99bc-113d57c98c32"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7Â Â Â Â Â DRUG INTERACTIONS</title>
               <effectiveTime value="20200506"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong and Moderate CYP3A Inducers</content>: Avoid concomitant use. (<linkHtml href="#s7p1">7.1</linkHtml>)
								</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s7p1">
                     <id root="d16f02a7-a97c-4fed-a2c9-afbabdca8a7c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1Â Â Â Â Â Effect of Other Drugs on TABRECTA</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Strong and Moderate CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s7p2">
                     <id root="c1fda032-aca6-49b2-b9a7-74469b0d6c0a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2Â Â Â Â Â Effect of TABRECTA on Other Drugs</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CYP1A2 Substrates</content>
                        </paragraph>
                        <paragraph>Coadministration of TABRECTA increased the exposure of a CYP1A2 substrate, which may increase the adverse reactions of these substrates <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. If coadministration is unavoidable between TABRECTA and CYP1A2 substrates where minimal concentration changes may lead to serious adverse reactions, decrease the CYP1A2 substrate dosage in accordance with the approved prescribing information.</paragraph>
                        <paragraph>
                           <content styleCode="underline">P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) Substrates</content>
                        </paragraph>
                        <paragraph>Coadministration of TABRECTA increased the exposure of a P-gp substrate and a BCRP substrate, which may increase the adverse reactions of these substrates <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. If coadministration is unavoidable between TABRECTA and P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions, decrease the P-gp or BCRP substrate dosage in accordance with the approved prescribing information.</paragraph>
                        <paragraph>
                           <content styleCode="underline">MATE1 and MATE2K Substrates</content>
                        </paragraph>
                        <paragraph>Coadministration of TABRECTA may increase the exposure of MATE1 and MATE2K substrates, which may increase the adverse reactions of these substrates <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. If coadministration is unavoidable between TABRECTA and MATE1 or MATE2K substrates where minimal concentration changes may lead to serious adverse reactions, decrease the MATE1 or MATE2K substrate dosage in accordance with the approved prescribing information.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="ec72611c-7838-44c3-99b6-69aabec26fa6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8Â Â Â Â Â USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20220810"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#s8p2">8.2</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8p1">
                     <id root="ae52da1f-e67d-432d-ba39-d1441d0a17a1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1Â Â Â Â Â Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings from animal studies and its mechanism of action <content styleCode="italics">[see Clinical Pharmacology (12.1)]</content>, TABRECTA can cause fetal harm when administered to a pregnant woman. There are no available data on TABRECTA use in pregnant women. Oral administration of capmatinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures less than the human exposure based on AUC at the 400 mg twice daily clinical dose (<content styleCode="italics">see Data</content>). Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In rats, maternal toxicity (reduced body weight gain and food consumption) occurred at 30 mg/kg/day (approximately 1.4 times the human exposure based on AUC at the 400 mg twice daily clinical dose). Fetal effects included reduced fetal weights, irregular/incomplete ossification, and increased incidences of fetal malformations (e.g., abnormal flexure/inward malrotation of hindpaws/forepaws, thinness of forelimbs, lack of/reduced flexion at the humerus/ulna joints, and narrowed or small tongue) at doses of â¥ 10 mg/kg/day (approximately 0.6 times the human exposure based on AUC at the 400 mg twice daily clinical dose).</paragraph>
                        <paragraph>In rabbits, no maternal effects were detected at doses up to 60 mg/kg/day (approximately 1.5 times the human exposure based on AUC at the 400 mg twice daily clinical dose). Fetal effects included small lung lobe at â¥ 5 mg/kg/day (approximately 0.016 times the human exposure based on AUC at the 400 mg twice daily clinical dose), and reduced fetal weights, irregular/incomplete ossification and increased incidences of fetal malformations (e.g., abnormal flexure/malrotation of hindpaws/forepaws, thinness of forelimbs/hindlimbs, lack of/reduced flexion at the humerus/ulna joints, small lung lobes, narrowed or small tongue) at the dose of 60 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s8p2">
                     <id root="5592c280-9635-4a92-86da-8bd7bd3a105b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>8.2Â Â Â Â Â Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of capmatinib or its metabolites in either human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with TABRECTA and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s8p3">
                     <id root="d2597634-4ef5-4324-bb96-c5c1fd5538b8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77291-3" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3Â Â Â Â Â Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Based on animal data, TABRECTA can cause malformations at doses less than the human exposure based on AUC at the 400 mg twice daily clinical dose <content styleCode="italics">[see Use in Specific Populations (8.1)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status for females of reproductive potential prior to starting treatment with TABRECTA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s8p4">
                     <id root="0547c5c9-bc06-4649-899a-e796934163bd"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4Â Â Â Â Â Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of TABRECTA in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section ID="s8p5">
                     <id root="e32761d5-b760-4ccf-809a-97a5b5d6beeb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5Â Â Â Â Â Geriatric Use</title>
                     <text>
                        <paragraph>In GEOMETRY mono-1, 61% of the 373 patients were 65 years or older and 18% were 75 years or older. No overall differences in the safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20220810"/>
                  </section>
               </component>
               <component>
                  <section ID="s8p6">
                     <id root="dcbd85eb-4bf2-4585-829e-a57695d2c48d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88828-9" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6Â Â Â Â Â Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is recommended in patients with mild (baseline creatinine clearance [CLcr] 60 to 89 mL/min by Cockcroft-Gault) or moderate renal impairment (CLcr 30 to 59 mL/min) <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>. TABRECTA has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min).</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="14a059d3-3a85-4351-900e-7657cbc35a0e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>11Â Â Â Â Â DESCRIPTION</title>
               <text>
                  <paragraph>Capmatinib is a kinase inhibitor. The chemical name is 2-Fluoro-<content styleCode="italics">N</content>-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-<content styleCode="italics">b</content>][1,2,4]triazin-2-yl]benzamideâhydrogen chlorideâwater (1/2/1). The molecular formula for capmatinib dihydrochloride monohydrate is C<sub>23</sub>H<sub>21</sub>Cl<sub>2</sub>FN<sub>6</sub>O<sub>2</sub>. The relative molecular mass is 503.36 g/mol for the dihydrochloride monohydrate salt and 412.43 g/mol for the free base. The chemical structure for capmatinib dihydrochloride monohydrate is shown below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000004"/>
                  </paragraph>
                  <paragraph>Capmatinib dihydrochloride monohydrate is a yellow powder with a pKa<sub>1</sub> of 0.9 (calculated) and pKa<sub>2</sub> of 4.5 (experimentally). Capmatinib dihydrochloride monohydrate is slightly soluble in acidic aqueous solutions at pH 1 and 2 and of further decreasing solubility towards neutral condition. The log of the distribution coefficient (n-octanol/acetate buffer pH 4.0) is 1.2.</paragraph>
                  <paragraph>TABRECTA is supplied for oral use as ovaloid, curved film-coated tablets with beveled edges, unscored containing 150 mg (pale orange brown color) or 200 mg (yellow color) capmatinib (equivalent to 183.00 mg or 244.00 mg respectively of capmatinib dihydrochloride monohydrate). Each tablet strength contains colloidal silicon dioxide; crospovidone; magnesium stearate; mannitol; microcrystalline cellulose; povidone; and sodium lauryl sulfate as inactive ingredients.</paragraph>
                  <paragraph>The 150 mg tablet coating contains ferric oxide, red; ferric oxide, yellow; ferrosoferric oxide; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide. The 200 mg tablet coating contains ferric oxide, yellow; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20230309"/>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>capmatinib dihydrochloride monohydrate structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="inc280-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2bd9ffef-5ccc-4566-b6a2-7fbfbfd7f7de"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12Â Â Â Â Â CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220121"/>
               <component>
                  <section>
                     <id root="012be61f-8325-468d-8c19-f48c7870c7a5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1Â Â Â Â Â Mechanism of Action</title>
                     <text>
                        <paragraph>Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling. Capmatinib inhibited cancer cell growth driven by a mutant MET variant lacking exon 14 at clinically achievable concentrations and demonstrated anti-tumor activity in murine tumor xenograft models derived from human lung tumors with either a mutation leading to MET exon 14 skipping or MET amplification. Capmatinib inhibited the phosphorylation of MET triggered by binding of hepatocyte growth factor or by MET amplification, as well as MET-mediated phosphorylation of downstream signaling proteins and proliferation and survival of MET-dependent cancer cells.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c05fad37-549a-4462-9584-cf6743340a1a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2Â Â Â Â Â Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exposure-Response</content>
                        </paragraph>
                        <paragraph>Capmatinib exposure-response relationships and the time course of pharmacodynamics response are unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>No large mean increase in QTc (i.e. &gt; 20 ms) was detected following treatment with TABRECTA at the recommended dosage of 400 mg orally twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bf179a88-ee56-4250-a4b9-a83abccfbbb7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3Â Â Â Â Â Pharmacokinetics</title>
                     <text>
                        <paragraph>Capmatinib exposure (AUC<sub>0-12h</sub> and C<sub>max</sub>) increased approximately proportionally over a dose range of 200 mg (0.5 times the recommended dosage) to 400 mg. Capmatinib reached steady-state by day 3 following twice daily dosing, with a mean (% coefficient of variation [%CV]) accumulation ratio of 1.5 (41%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>After administration of TABRECTA 400 mg orally in patients with cancer, capmatinib peak plasma concentrations (C<sub>max</sub>) were reached in approximately 1 to 2 hours (T<sub>max</sub>). The absorption of capmatinib after oral administration is estimated to be greater than 70%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>
									A high-fat meal (containing approximately 1000 calories and 50% fat) in healthy subjects increased capmatinib AUC<sub>0-INF</sub> by 46% with no change in C<sub>max</sub> compared to under fasted conditions. A low-fat meal (containing approximately 300 calories and 20% fat) in healthy subjects had no clinically meaningful effect on capmatinib exposure. When capmatinib was administered at 400 mg orally twice daily in cancer patients, exposure (AUC<sub>0-12h</sub>) was similar after administration of capmatinib with food and under fasted conditions.
								</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Capmatinib plasma protein binding is 96%, independent of capmatinib concentration. The apparent mean volume of distribution at steady-state is 164 L.</paragraph>
                        <paragraph>The blood-to-plasma ratio was 1.5, but decreased at higher concentrations to 0.9.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The effective elimination half-life of capmatinib is 6.5 hours. The mean (%CV) steady-state apparent clearance of capmatinib is 24 L/hr (82%).
								</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Capmatinib is primarily metabolized by CYP3A4 and aldehyde oxidase.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following a single oral administration of radiolabeled-capmatinib to healthy subjects, 78% of the total radioactivity was recovered in feces with 42% as unchanged and 22% was recovered in urine with negligible as unchanged.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified for the following covariates assessed: age (26 to 90 years), sex, race (White, Asian, Native American, Black, unknown), body weight (35 to 131 kg), mild to moderate renal impairment (baseline CLcr 30 to 89 mL/min by Cockcroft-Gault) and mild, moderate or severe hepatic impairment (Child-Pugh classification). The effect of severe renal impairment (baseline CLcr 15 to 29  mL/min) on capmatinib pharmacokinetics has not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A Inhibitors:</content> Coadministration with itraconazole (a strong CYP3A inhibitor) increased capmatinib AUC<sub>0-INF</sub> by 42% with no change in capmatinib C<sub>max</sub>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A Inducers:</content> Coadministration with rifampicin (a strong CYP3A inducer) decreased capmatinib AUC<sub>0-INF</sub> by 67% and decreased C<sub>max</sub> by 56%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Moderate CYP3A Inducers:</content> Coadministration with efavirenz (a moderate CYP3A inducer) was predicted to decrease capmatinib AUC<sub>0-12h</sub> by 44% and decrease C<sub>max</sub> by 34%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Proton Pump Inhibitors:</content> Coadministration with rabeprazole (a proton pump inhibitor) decreased capmatinib AUC<sub>0-INF</sub> by 25% and decreased C<sub>max</sub> by 38%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Substrates of CYP Enzymes:</content> Coadministration of capmatinib increased caffeine (a CYP1A2 substrate) AUC<sub>0-INF</sub> by 134% with no change in its C<sub>max</sub>. Coadministration of capmatinib had no clinically meaningful effect on exposure of midazolam (a CYP3A substrate).</paragraph>
                        <paragraph>
                           <content styleCode="italics">P-gp Substrates:</content> Coadministration of capmatinib increased digoxin (a P-gp substrate) AUC<sub>0-INF</sub> by 47% and increased C<sub>max</sub> by 74%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">BCRP Substrates:</content> Coadministration of capmatinib increased rosuvastatin (a BCRP substrate) AUC<sub>0-INF</sub> by 108% and increased C<sub>max</sub> by 204%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems:</content> Capmatinib is a substrate of P-gp, but not a substrate of BCRP or MRP2. Capmatinib reversibly inhibits MATE1 and MATE2K, but does not inhibit OATP1B1, OATP1B3, OCT1, OAT1, OAT3, or MRP2.</paragraph>
                     </text>
                     <effectiveTime value="20220121"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9d2aa1cf-f7a1-4a7c-a8c9-b2d464ff2a1e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13Â Â Â Â Â NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20200506"/>
               <component>
                  <section>
                     <id root="b33a7bf1-9b42-4232-b988-2c6b1ec6c6c5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1Â Â Â Â Â Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies were not conducted with capmatinib. Capmatinib was not mutagenic in an in vitro bacterial reverse mutation assay and did not cause chromosomal aberrations in an in vitro chromosome aberration assay in human peripheral blood lymphocytes. Capmatinib was not clastogenic in an in vivo bone marrow micronucleus test in rats.</paragraph>
                        <paragraph>Dedicated fertility studies were not conducted with capmatinib. No effects on male and female reproductive organs occurred in general toxicology studies conducted in rats and monkeys at doses resulting in exposures of up to approximately 3.6 times the human exposure based on AUC at the 400 mg twice daily clinical dose.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="50acbbc4-ba4b-4a7d-bf9c-ab90eed8c020"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34091-9" displayName=" ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION "/>
                     <title>13.2Â Â Â Â Â Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In rats, capmatinib administration resulted in vacuolation of white matter of the brain in both 4- and 13-week studies at doses â¥ 2.2 times the human exposure (AUC) at the 400 mg twice daily clinical dose. In some cases, the brain lesions were associated with early death and/or convulsions or tremors. Concentrations of capmatinib in the brain tissue of rats was approximately 9% of the corresponding concentrations in plasma.</paragraph>
                        <paragraph>In vitro and in vivo assays demonstrated that capmatinib has some potential for photosensitization; however, the no-observed-adverse-effect level for in vivo photosensitization was 30 mg/kg/day (C<sub>max</sub> of 14000 ng/mL), about 2.9 times the human C<sub>max</sub> at the 400 mg twice daily clinical dose.</paragraph>
                     </text>
                     <effectiveTime value="20200506"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="54bd39bd-0fec-429f-9df8-e00496fd5cab"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>14Â Â Â Â Â CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Metastatic NSCLC with a Mutation that Leads to MET Exon 14 Skipping</content>
                  </paragraph>
                  <paragraph>The efficacy of TABRECTA was evaluated in GEOMETRY mono-1, a multicenter, non-randomized, open-label, multi-cohort study (NCT02414139). Eligible patients were required to have NSCLC with a mutation that leads to MET exon 14 skipping, epidermal growth factor receptor (EGFR) wild-type and anaplastic lymphoma kinase (ALK) negative status, and at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients with symptomatic CNS metastases, clinically significant uncontrolled cardiac disease, or who received treatment with any MET or hepatocyte growth factor (HGF) inhibitor were not eligible for the study.</paragraph>
                  <paragraph>Out of the first 97 patients enrolled in GEOMETRY mono-1 following the central confirmation of MET exon 14 skipping by a RNA-based clinical trial assay, 78 patient samples were retested with the FDA-approved FoundationOne<sup>Â®</sup> CDx (22 treatment-naÃ¯ve and 56 previously treated patients) to detect mutations that lead to MET exon 14 skipping. Out of 78 samples retested with FoundationOne<sup>Â®</sup> CDx, 73 samples were evaluable (20 treatment-naÃ¯ve and 53 previously treated patients), 72 (20 treatment-naÃ¯ve and 52 previously treated patients) of which were confirmed to have a mutation that leads to MET exon 14 skipping, demonstrating an estimated positive percentage agreement of 99% (72/73) between the clinical trial assay and the FDA-approved assay.</paragraph>
                  <paragraph>Patients received TABRECTA 400 mg orally twice daily until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR) as determined by a Blinded Independent Review Committee (BIRC) according to RECIST 1.1. An additional efficacy outcome measure was duration of response (DOR) by BIRC.</paragraph>
                  <paragraph>The efficacy population included 60 treatment-naÃ¯ve patients and 100 previously treated patients. The median age was 71 years (range: 48 to 90 years); 61% female; 77% White; 25% had Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 and 74% had ECOG PS 1; 61% never smoked; 83% had adenocarcinoma; and 16% had CNS metastases. Among previously treated patients, 81% received one, 16% received two and 3% received three prior lines of systemic therapy. Amongst previously treated patients, 86% received prior platinum-based chemotherapy.</paragraph>
                  <paragraph>Efficacy results are presented in Table 5.</paragraph>
                  <table>
                     <caption>Table 5: Efficacy Results for Treatment-NaÃ¯ve and Previously Treated Patients in GEOMETRY mono-1</caption>
                     <col width="450"/>
                     <col width="285"/>
                     <col width="285"/>
                     <tfoot>
                        <tr>
                           <td colspan="3">Abbreviations: CI, confidence interval; NE, not estimable.<br/>
                              <sup>a</sup>Blinded Independent Review Committee (BIRC) review.<br/>
                              <sup>b</sup>Confirmed response.<br/>
                              <sup>c</sup>Clopper and Pearson exact binomial 95% CI.<br/>
                              <sup>d</sup>Based on Kaplan-Meier estimate.
									</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">Efficacy parameters</content>
                           </td>
                           <td align="center">
                              <content styleCode="bold">Treatment-naÃ¯ve<br/>N = 60</content>
                           </td>
                           <td align="center">
                              <content styleCode="bold">Previously treated<br/>N = 100</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule" align="left">
                              <content styleCode="bold">Overall response rate<sup>a,b</sup>
                              </content> (95% CI)<sup>c</sup>
                           </td>
                           <td styleCode="Toprule" align="center">68% (55, 80)</td>
                           <td styleCode="Toprule" align="center">44% (34, 54)</td>
                        </tr>
                        <tr>
                           <td>Â Â Â Â Â Complete response</td>
                           <td align="center">5%</td>
                           <td align="center">0</td>
                        </tr>
                        <tr>
                           <td>Â Â Â Â Â Partial response</td>
                           <td align="center">63%</td>
                           <td align="center">44%</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left">
                              <content styleCode="bold">Duration of response (DOR)<sup>a</sup>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td>Â Â Â Â Â Median (months) (95% CI)<sup>d</sup>
                           </td>
                           <td align="center">16.6 (8.4, 22.1)</td>
                           <td align="center">9.7 (5.6, 13.0)</td>
                        </tr>
                        <tr>
                           <td>Â Â Â Â Â Patients % with DOR â¥ 12 months</td>
                           <td align="center">49%</td>
                           <td align="center">36%</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240314"/>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="c462febc-037e-410f-b5b9-df70f0e33e51"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>16Â Â Â Â Â HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <table>
                     <caption>TABRECTA (capmatinib) 150 mg and 200 mg tablets</caption>
                     <col width="200"/>
                     <col width="400"/>
                     <col width="200"/>
                     <col width="200"/>
                     <tbody>
                        <tr>
                           <td align="center">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="center">
                              <content styleCode="bold">Description</content>
                           </td>
                           <td align="center">
                              <content styleCode="bold">Tablets per bottle</content>
                           </td>
                           <td align="center">
                              <content styleCode="bold">NDC number</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Toprule " valign="top">150 mg</td>
                           <td styleCode="Toprule">Pale orange brown, ovaloid, curved film-coated tablet with beveled edges, unscored, debossed with âDUâ on one side and âNVRâ on the other side.</td>
                           <td align="center" styleCode="Toprule " valign="top">56</td>
                           <td align="center" styleCode="Toprule " valign="top">0078-0709-56</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Toprule " valign="top">200 mg</td>
                           <td styleCode="Toprule">Yellow, ovaloid, curved film-coated tablet with beveled edges, unscored, debossed with âLOâ on one side and âNVRâ on the other side.</td>
                           <td align="center" styleCode="Toprule " valign="top">56</td>
                           <td align="center" styleCode="Toprule " valign="top">0078-0716-56</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Dispense in the original package with the desiccant cartridge. Store at 20Â°C to 25Â°C (68Â°F to 77Â°F), excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) [see USP Controlled Room Temperature]. Protect from moisture.</paragraph>
                  <paragraph>Discard any unused TABRECTA remaining after 6 weeks of first opening the bottle.</paragraph>
               </text>
               <effectiveTime value="20230324"/>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="3d6a182c-1717-44f1-bc3b-220106191b93"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17Â Â Â Â Â PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Interstitial Lung Disease (ILD)/Pneumonitis</content>
                  </paragraph>
                  <paragraph>Inform patients of the risks of severe or fatal ILD/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Inform patients that they will need to undergo lab tests to monitor liver function. Advise patients to immediately contact their healthcare provider for signs and symptoms of liver dysfunction <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pancreatic Toxicity</content>
                  </paragraph>
                  <paragraph>Inform patients that they will need to undergo lab tests to monitor pancreatic function. Advise patients to immediately contact their healthcare provider for signs and symptoms of pancreatitis <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients that there is a risk of hypersensitivity reactions with TABRECTA. Advise patients to stop taking TABRECTA and immediately contact their healthcare provider for signs and symptoms of hypersensitivity <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risk of Photosensitivity</content>
                  </paragraph>
                  <paragraph>Inform patients that there is a potential risk of photosensitivity reactions with TABRECTA. Advise patients to limit direct ultraviolet exposure by using sunscreen or protective clothing during treatment with TABRECTA <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (5.6), Use in Specific Populations (8.1)]</content>.</paragraph>
                  <paragraph>Advise females of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (8.3)]</content>.</paragraph>
                  <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with TABRECTA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (8.3)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products <content styleCode="italics">[see Drug Interactions (7)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with TABRECTA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (8.2)]</content>.</paragraph>
                  <paragraph>Distributed by:<br/>Novartis Pharmaceuticals Corporation<br/>East Hanover, New Jersey 07936</paragraph>
                  <paragraph>Â© Novartis</paragraph>
                  <paragraph>T2024-19</paragraph>
               </text>
               <effectiveTime value="20240314"/>
            </section>
         </component>
         <component>
            <section>
               <id root="307df570-66d1-44d6-9a74-8bf9b0211aab"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table width="100%">
                     <col width="34%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tfoot>
                        <tr>
                           <td colspan="2">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: March 2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Toprule " align="center">
                              <content styleCode="bold">PATIENT INFORMATION<br/>TABRECTA<sup>Â®</sup> (ta brek tah)<br/>(capmatinib) tablets</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">What is TABRECTA?</content>
                              <br/>TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:
										<list>
                                 <item>has spread to other parts of the body (metastatic), and</item>
                                 <item>whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your healthcare provider will perform a test to make sure that TABRECTA is right for you.</item>
                              </list>It is not known if TABRECTA is safe and effective in children.
									</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">Before taking TABRECTA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list>
                                 <item>have or have had lung or breathing problems other than your lung cancer</item>
                                 <item>have or have had liver problems</item>
                                 <item>have or have had pancreatic problems</item>
                                 <item>are pregnant or plan to become pregnant. TABRECTA can harm your unborn baby.<br/>
                                    <content styleCode="bold">Females</content> who are able to become pregnant:
												<list>
                                       <item>Your healthcare provider should do a pregnancy test before you start your treatment with TABRECTA.</item>
                                       <item>You should use effective birth control during treatment and for 1 week after your last dose of TABRECTA. Talk to your healthcare provider about birth control choices that might be right for you during this time.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TABRECTA.</item>
                                    </list>
                                    <content styleCode="bold">Males</content> who have female partners who can become pregnant:
												<list>
                                       <item>You should use effective birth control during treatment and for 1 week after your last dose of TABRECTA.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TABRECTA passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of TABRECTA.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take, including</content> prescription and over-the-counter medicines, vitamins, and herbal supplements.
									</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">How should I take TABRECTA?</content>
                              <list>
                                 <item>Take TABRECTA exactly as your healthcare provider tells you.</item>
                                 <item>Take TABRECTA 2 times a day with or without food.</item>
                                 <item>Swallow TABRECTA tablets whole. Do not break, crush, or chew TABRECTA tablets.</item>
                                 <item>Do not change your dose or stop taking TABRECTA unless your healthcare provider tells you to.</item>
                                 <item>If you miss or vomit a dose of TABRECTA, <content styleCode="bold">do not</content> make up the dose. Take your next dose at your regular scheduled time.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">What should I avoid while taking TABRECTA?</content>
                              <list>
                                 <item>Your skin may be sensitive to the sun (photosensitivity) during treatment with TABRECTA. Use sunscreen or wear clothes that cover your skin during your treatment with TABRECTA to limit direct sunlight exposure.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">What are the possible side effects of TABRECTA?<br/>TABRECTA may cause serious side effects, including:</content>
                              <list>
                                 <item>
                                    <content styleCode="bold">Lung or breathing problems.</content> TABRECTA may cause inflammation of the lungs that can cause death. Tell your healthcare provider right away if you develop any new or worsening symptoms, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">Â Â Â Â Â Â â¦Â Â cough</td>
                           <td align="left" valign="top">Â Â Â Â Â Â â¦Â Â fever</td>
                           <td styleCode="Rrule" align="left" valign="top">Â Â Â Â Â Â â¦Â Â trouble breathing or shortness of breath</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">
                              <list>
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> TABRECTA may cause abnormal liver blood test results. Your healthcare provider will do blood tests to check your liver function before you start treatment and during treatment with TABRECTA. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">Â Â Â Â Â Â â¦Â Â your skin or the white part of your eyes turns yellow (jaundice)<br/>Â Â Â Â Â Â â¦Â Â dark or âtea-coloredâ urine<br/>Â Â Â Â Â Â â¦Â Â light-colored stools (bowel movements)<br/>Â Â Â Â Â Â â¦Â Â confusion<br/>Â Â Â Â Â Â â¦Â Â tiredness<br/>Â Â Â Â Â Â â¦Â Â loss of appetite for several days or longer</td>
                           <td styleCode="Rrule" colspan="2" valign="top">Â Â Â Â Â Â Â â¦Â Â nausea and vomiting<br/>Â Â Â Â Â Â Â â¦Â Â pain, aching, or tenderness on the right side of your stomach-area (abdomen)<br/>Â Â Â Â Â Â Â â¦Â Â weakness<br/>Â Â Â Â Â Â Â â¦Â Â swelling in your stomach-area</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">
                              <list>
                                 <item>
                                    <content styleCode="bold">Pancreas problems</content>. TABRECTA may cause increases in your blood amylase and/or lipase levels that may indicate a problem with your pancreas. Your healthcare provider will do blood tests to check your pancreatic function before you start treatment and during treatment with TABRECTA. Tell your healthcare provider right away if you develop any signs and symptoms of pancreas problems, including:
												<list>
                                       <item>upper stomach (abdominal) pain that may spread to your back and get worse with eating</item>
                                       <item>weight loss</item>
                                       <item>nausea</item>
                                       <item>vomiting</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">
                              <list>
                                 <item>
                                    <content styleCode="bold">Allergic reactions.</content> TABRECTA can cause an allergic reaction. Stop taking TABRECTA and tell your healthcare provider right away if you get any signs and symptoms of an allergic reaction, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left" valign="top">Â Â Â Â Â Â â¦Â Â fever<br/>Â Â Â Â Â Â â¦Â Â chills<br/>Â Â Â Â Â Â â¦Â Â itching<br/>Â Â Â Â Â Â â¦Â Â rash</td>
                           <td styleCode="Rrule" colspan="2" valign="top">Â Â Â Â Â Â Â â¦Â Â dizziness or feeling faint<br/>Â Â Â Â Â Â Â â¦Â Â nausea<br/>Â Â Â Â Â Â Â â¦Â Â vomiting</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">
                              <list>
                                 <item>
                                    <content styleCode="bold">Risk of sensitivity to sunlight (photosensitivity).</content> See <content styleCode="bold">âWhat should I avoid while taking TABRECTA?â</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">
                              <content styleCode="bold">The most common side effects of TABRECTA include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">Â Â Â Â Â â¢	swelling of your hands or feet<br/>Â Â Â Â Â â¢	nausea<br/>Â Â Â Â Â â¢	muscle or bone pain<br/>Â Â Â Â Â â¢	tiredness and weakness<br/>Â Â Â Â Â â¢	vomiting</td>
                           <td styleCode="Rrule" colspan="2">Â Â Â Â Â â¢	trouble breathing<br/>Â Â Â Â Â â¢	cough<br/>Â Â Â Â Â â¢	loss of appetite<br/>Â Â Â Â Â â¢	changes in certain blood tests</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule" colspan="3">Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TABRECTA if you develop certain side effects.<br/>These are not all of the possible side effects of TABRECTA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">How should I store TABRECTA?</content>
                              <list>
                                 <item>Store TABRECTA at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                                 <item>Store TABRECTA in the original package with the drying agent (desiccant) cartridge.</item>
                                 <item>Protect TABRECTA from moisture.</item>
                                 <item>Throw away (discard) any unused TABRECTA you have left after 6 weeks of first opening the bottle.</item>
                              </list>
                              <content styleCode="bold">Keep TABRECTA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">General information about the safe and effective use of TABRECTA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TABRECTA for a condition for which it was not prescribed. Do not give TABRECTA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TABRECTA that is written for health professionals.
									</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Rrule Lrule" colspan="3">
                              <content styleCode="bold">What are the ingredients in TABRECTA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> capmatinib<br/>
                              <content styleCode="bold">Inactive ingredients:</content> Tablet core: colloidal silicon dioxide; crospovidone; magnesium stearate; mannitol; microcrystalline cellulose; povidone; and sodium lauryl sulfate.<br/>Tablet coating (150 mg): ferric oxide, red; ferric oxide, yellow; ferrosoferric oxide; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide.<br/>Tablet coating (200 mg): ferric oxide, yellow; hypromellose; polyethylene glycol (PEG) 4000; talc; and titanium dioxide.<br/>
                              <br/>Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936<br/>For more information, go to www.TABRECTA.com or call 1-888-669-6682.<br/>Â© Novartis
									</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>T2025-11</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section>
               <id root="0ffa72ec-59a7-4e27-a5d8-f7434039535e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0078-0709-56</paragraph>
                  <paragraph>TABRECTA<sub>Â®</sub>
                  </paragraph>
                  <paragraph>(capmatinib) tablets</paragraph>
                  <paragraph>150 mg<sup>*</sup>
                  </paragraph>
                  <paragraph>Attention: Dispense and store Tabrecta<br/>
						in original container with the desiccant<br/>to protect from moisture.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>56 Film-coated tablets</paragraph>
                  <paragraph>NOVARTIS</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0000004"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230601"/>
               <component>
                  <observationMedia ID="MM0000004">
                     <text>PRINCIPAL DISPLAY PANEL
								NDC 0078-0709-56
								TABRECTAÂ®
								(capmatinib) tablets
								150 mg*
								Attention: Dispense and store Tabrecta
								in original container with the desiccant
								to protect from moisture.
								Rx only
								56 Film-coated tablets
								NOVARTIS
							</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="inc280-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="46f97442-cf40-4ff6-87e0-42505d63fcfc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0078-0716-56</paragraph>
                  <paragraph>TABRECTA<sub>Â®</sub>
                  </paragraph>
                  <paragraph>(capmatinib) tablets</paragraph>
                  <paragraph>200 mg<sup>*</sup>
                  </paragraph>
                  <paragraph>Attention: Dispense and store Tabrecta<br/>
						in original container with the desiccant<br/>to protect from moisture.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>56 Film-coated tablets</paragraph>
                  <paragraph>NOVARTIS</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0000005"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230601"/>
               <component>
                  <observationMedia ID="MM0000005">
                     <text>PRINCIPAL DISPLAY PANEL
								NDC 0078-0716-56
								TABRECTAÂ®
								(capmatinib) tablets
								200 mg*
								Attention: Dispense and store Tabrecta
								in original container with the desiccant
								to protect from moisture.
								Rx only
								56 Film-coated tablets
								NOVARTIS</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="inc280-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>